Bedaquiline resistance in tuberculosis: mechanisms, implications, and strategies to preserve efficacy
The Egyptian Journal of Chest Diseases and Tuberculosis · 2026-07 · 75 (3) · 265-276
DOI: 10.4103/ecdt.ecdt_65_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Egyptian Journal of Chest Diseases and Tuberculosis, online erschienen am 10.07.2026. Verfasst von Muhammad M. Hasnain und 5 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) remains a significant global health challenge, particularly due to its capacity to develop resistance to treatment. Once regarded as a nearly untreatable disease, TB has evolved with the emergence of multidrug-resistant TB, complicating management efforts. In response to increasing drug resistance, bedaquiline was introduced in 2012 as the first new anti-TB drug in over 50 years explicitly designed to combat multidrug-resistant TB. Bedaquiline targets mycobacterial ATP synthase, disrupting energy production and leading to bacterial cell death. However, resistance to this drug has emerged, often linked to gene mutations such as atpE and mmpR5 (Rv0678), which can reduce its effectiveness. This review explores the mechanisms driving bedaquiline resistance and its impact on TB treatment outcomes. It highlights the critical role of drug susceptibility testing in developing personalized treatment plans and emphasizes the need for enhanced surveillance, research into combination therapies, and clinical trials to address resistance. Given the growing burden of drug resistance to TB, this review aims to provide valuable insights for clinicians and public health professionals on optimizing bedaquiline use, mitigating resistance, and improving treatment success. As TB treatment strategies continue to evolve, ongoing research and vigilance are essential to preserving the efficacy of available therapies.
Zitieren
APA
Hasnain, M. M., Haider, M. U., Hussain, H. I., Manzoor, Z., Ahmad, S., & Taqi, M. H. (2026). Bedaquiline resistance in tuberculosis: mechanisms, implications, and strategies to preserve efficacy. The Egyptian Journal of Chest Diseases and Tuberculosis, 75(3), 265-276. https://doi.org/10.4103/ecdt.ecdt_65_25
Vancouver
Hasnain MM, Haider MU, Hussain HI, Manzoor Z, Ahmad S, Taqi MH. Bedaquiline resistance in tuberculosis: mechanisms, implications, and strategies to preserve efficacy. The Egyptian Journal of Chest Diseases and Tuberculosis. 2026;75(3):265-276. doi:10.4103/ecdt.ecdt_65_25
BibTeX
@article{Hasnain2026,
author = {Hasnain, Muhammad M. and Haider, Muhammad U. and Hussain, Hafiz I. and Manzoor, Zahid and Ahmad, Sajjad and Taqi, Muhammad H.},
title = {Bedaquiline resistance in tuberculosis: mechanisms, implications, and strategies to preserve efficacy},
journal = {The Egyptian Journal of Chest Diseases and Tuberculosis},
year = {2026},
volume = {75},
number = {3},
pages = {265--276},
doi = {10.4103/ecdt.ecdt_65_25}
}
EUVIMED